Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- PI +12.5%, NNBR +4.7% (guidance), EOLS +4.5%, PRGS +4%
Other news:
- NTRA +8.1% (verdict reached in patent case; no willful infringement damages significantly less than what Ravgen was seeking)
- RCUS +4.9% (RCUS announces survival data from ARC-8 a Phase 1b study co-developed with GILD)
- TFPM +3.5% (reports Q4 revenue above consensus metal sales of 26243 gold equivalent ounces)
- IXHL +3.4% (received approval to commence a Phase 2/3 clinical trial)
- SBGI +2.1% (announces global settlement of all diamond sports group-related litigation issues including agreement with diamond on management services agreement amendment)
- NRIX +1.9% (receives FDA Fast Track Designation for NX-5948)
- ENLC +1.8% (expands 2023 common unit repurchase auth of $250 mln authorizes 2024 $200 mln repurchase plan increases distribution)
- EU +1.8% (provides update on South Texas uranium operations)
- ALB +1.6% (outlined a series of proactive measures underway to re-phase its organic growth investments and optimize its cost structure)
- REPX +0.9% (reduces debt outstanding by $30 mln)
- CBUS +0.8% (announces that the Company is moving forward in the next step of commercialization of its developed traits) .
Analyst comments:
- CART +3% (upgraded to Outperform from Peer Perform at Wolfe Research)
- EXLS +1.5% (upgraded to Buy from Neutral at Citigroup)